<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9483">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05696899</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-68138</org_study_id>
    <nct_id>NCT05696899</nct_id>
  </id_info>
  <brief_title>Determining the Efficacy of Essential Oil Aromatherapy in Children Undergoing Port Access</brief_title>
  <official_title>Determining the Efficacy of Essential Oil Aromatherapy in Children Undergoing Port Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of aromatherapy impacts patient anxiety&#xD;
      and pain scores surrounding port access in pediatric oncology patients between the ages of 4&#xD;
      years and 18 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific aims include the following:&#xD;
&#xD;
      Aim 1: To compare pre and post port access anxiety scores for both control and intervention&#xD;
      groups.&#xD;
&#xD;
      Aim 2: To assess pre and post port pain scores surrounding port access for both control and&#xD;
      intervention groups.&#xD;
&#xD;
      Aim 3: To compare pain and anxiety scores between age groups. The overall goal of this pilot&#xD;
      study is to identify if aromatherapy, using non-topical, STILL QuickTAB Medipack blended&#xD;
      scent aromatherapy, manufactured by Soothing Scents, is effective as a valid&#xD;
      non-pharmacologic supplementation in reducing anxiety and pain scores during port access in&#xD;
      pediatric oncology patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of aromatherapy on post patient anxiety scores</measure>
    <time_frame>5 minutes</time_frame>
    <description>Comparison of pre and post patient anxiety scores for both control and intervention groups.&#xD;
Anxiety score will be measured by using the Visual Facial Anxiety Scale (VFAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of aromatherapy on post patient pain scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>Comparison of pre and post patient pain scale for both control and intervention groups.&#xD;
Pain scale will be measured by using, either Wong-Baker Faces or 0 to 10. Score range: 0 to 10 (0 = no pain, 10 = worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of aromatherapy on pre and post patient port pain scores</measure>
    <time_frame>up to 7 minutes</time_frame>
    <description>Comparison of pre and post port pain scores surrounding port access for both control and intervention groups.&#xD;
Pain scores will be measured by using either Wong-Baker Faces or 0-10, with higher scores indicating the worst pain level.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Aromatherapy effect according to age</measure>
    <time_frame>up to 7 minutes</time_frame>
    <description>To compare pre and post pain and anxiety scores between the three age groups.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Anxiety and Fear</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Aromatherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given STILL QuickTAB Medipack blended scent aromatherapy in addition to standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be offered standard supportive measures, which include numbing cream, Child Life support, distraction, caregiver hold, or any combination of these, based on patient preference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STILL QuickTAB Medipack blended scent aromatherapy, manufactured by Soothing Scents</intervention_name>
    <description>A resealable quick-tab dispenser with the 'therapeutic inhaled essential oils' lavender, bergamot, sweet orange, and ylang ylang.</description>
    <arm_group_label>Aromatherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children between 4 years and 18 years&#xD;
&#xD;
          2. Scheduled for port access with or without lab draw&#xD;
&#xD;
          3. Oncology, neuro-oncology, and stem cell transplant patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. has asthma, reactive airway disease, or allergies to any of the ingredients we are&#xD;
             using in the aromatherapy study (lavender, bergamot, sweet orange, and ylang ylang)&#xD;
&#xD;
          2. currently uses aromatherapy for port accesses or other painful procedures (does not&#xD;
             apply to patients using aromatherapy, such as peppermint oil, for nausea)&#xD;
&#xD;
          3. has a cognitive impairment that prevents them from being able to provide anxiety or&#xD;
             pain scores&#xD;
&#xD;
          4. does not wish to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Nasr, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renee A Nolen, MSN</last_name>
    <phone>573-823-8296</phone>
    <email>rnolen@stanfordchildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Nasr, PhD</last_name>
    <phone>650-498-5602</phone>
    <email>anasr@stanfordchildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Renee A Nolen, MSN, RN</last_name>
      <phone>573-823-8296</phone>
      <email>rnolen@stanfordchildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bikmoradi A, Khaleghverdi M, Seddighi I, Moradkhani S, Soltanian A, Cheraghi F. Effect of inhalation aromatherapy with lavender essence on pain associated with intravenous catheter insertion in preschool children: A quasi-experimental study. Complement Ther Clin Pract. 2017 Aug;28:85-91. doi: 10.1016/j.ctcp.2017.05.008. Epub 2017 May 24.</citation>
    <PMID>28779942</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghaderi F, Solhjou N. The effects of lavender aromatherapy on stress and pain perception in children during dental treatment: A randomized clinical trial. Complement Ther Clin Pract. 2020 Aug;40:101182. doi: 10.1016/j.ctcp.2020.101182. Epub 2020 Apr 28.</citation>
    <PMID>32891272</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang HJ, Nam ES, Lee Y, Kim M. How Strong is the Evidence for the Anxiolytic Efficacy of Lavender?: Systematic Review and Meta-analysis of Randomized Controlled Trials. Asian Nurs Res (Korean Soc Nurs Sci). 2019 Dec;13(5):295-305. doi: 10.1016/j.anr.2019.11.003. Epub 2019 Nov 16.</citation>
    <PMID>31743795</PMID>
  </results_reference>
  <results_reference>
    <citation>Karaman T, Karaman S, Dogru S, Tapar H, Sahin A, Suren M, Arici S, Kaya Z. Evaluating the efficacy of lavender aromatherapy on peripheral venous cannulation pain and anxiety: A prospective, randomized study. Complement Ther Clin Pract. 2016 May;23:64-8. doi: 10.1016/j.ctcp.2016.03.008. Epub 2016 Mar 25.</citation>
    <PMID>27157961</PMID>
  </results_reference>
  <results_reference>
    <citation>Kucuk Alemdar D, Yaman Aktas Y. The Use of the Buzzy, Jet Lidokaine, Bubble-blowing and Aromatherapy for Reducing Pediatric Pain, Stress and Fear Associated with Phlebotomy. J Pediatr Nurs. 2019 Mar-Apr;45:e64-e72. doi: 10.1016/j.pedn.2019.01.010. Epub 2019 Jan 30.</citation>
    <PMID>30711327</PMID>
  </results_reference>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 13, 2023</study_first_submitted>
  <study_first_submitted_qc>January 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 23, 2023</last_update_submitted>
  <last_update_submitted_qc>January 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aromatherapy</keyword>
  <keyword>Port-a-Cath</keyword>
  <keyword>Pediatric</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

